Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Narrative Review

Vol. 6 No. 2 (2002)

The Use of Fibrinolytic Therapy in Acute Ischemic Events

  • Danny Del Duca
DOI
https://doi.org/10.26443/mjm.v6i2.775
Submitted
November 19, 2020
Published
2020-12-01

Abstract

The loss of tissue perfusion represents the pathological basis underlying acute cerebrovascular events. The occlusion of the brain's blood supply by intravascular thrombotic and/or atherosclerotic phenomena results in a disruption in tissue oxygen and glucose delivery. This inevitably impairs the cell's capacity to synthesize ATP. Despite initial attempts to maintain consistent ATP stores through anaerobic glycolysis and adenosine release, the starving tissue experiences loss of membrane ionic gradients, secondary to the inactivation of the Na+/K+ ATPase pump. A significant increase in intracellular calcium concentration is triggered by the activation of voltage- gated calcium channels, the activation of ligand-gated calcium channels, and by the inactivation of the Na+/Ca+ exchanger. In addition, massive release of the main excitatory, inhibitory, and monoamine neurotransmitters (many of which become excitotoxins at high concentration) is also observed. The above excitatory transmitters, such as glutamine, for example, play an important role in the over-stimulation of the NMDA receptor, which in turn promotes excessive calcium influx (1). The cytotoxic effects of calcium are associated with the activation of lipases, proteases, and endonucleases, as well as xanthine oxidase and neuronal NO synthase, capable of either direct or indirect destruction of cellular structures (2).

References

  1. MacDermott AB., Mayer ML, Westbrook GL, Smith SJ., and Barker JL. (1986). NMDAreceptor activation increases cytoplasmic calcium concentration in cultured spinal chord neurons. Nature, 321: 519-522.
  2. Choi DW. (1995). Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634.
  3. Hardman and Limbird: Goodman and Gilman's The pharmacological basis of therapeutics, 10th ed., McGraw-Hill, 2001.
  4. Cotran: Robbins Pathologic Basis of Disease, 6th ed., W. B. Saunders Company, 1999.
  5. Lindsberg PJ, Roine RO, Tatlisumak T, et al. The future of stroke management. Neurologic Clinics 2000;18:495-510.
  6. Katzan IL, Sila CA, Furlan AJ. Community use of intravenous tissue plasminogen activator for acute stroke. Results of the Brain Matters Stroke Management Survey. Stroke 2001;2:861- 865.
  7. Fieschi C, Argentino C., Lenzi GL, Sacchetti ML, et al. (1989). Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. Journal of Neuroscience 91: 311-322.
  8. The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine, 333:1581-1587.
  9. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, et al. (1999). Effects of tissue plasminogen activator for acute ischemic stroke at one year. New England Journal of Medicine 340:1781-1787.
  10. Clark WM, Wissman S, Albers G, et al. Recombinant tissue- type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA 1999;282:2019-2026.
  11. Katzan IL, Furlan A.J, Lloyd LE, Frank JI, et al. (2000). Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland Area Experience. Journal of the American Medical Association 283: 1151-1158.
  12. Karbalai H, Demchuk AM, Hoyte KM, Klein GM, et al. (1999). Effectiveness of tissue-type plasminogen activator for ischemic stroke: consequences of protocol violation. Oral presentation at: 240th American Heart Association International Conference on Stroke and Cerebral Circulation; February 5, 1999; Nashville, Tennessee.
  13. Tanne D, Demchuk A, Kasner SE, et al. (1999). A large multinational investigation to predict t-PA-related symptomatic ICH in patients with acute ischemic stroke. Stroke, 30: 248. 128 McGill Journal of Medicine 2002
  14. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
  15. Hacke W, Kaste M, Fieschi C, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998;352:1245-1251.
  16. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator- related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34-39.
  17. Clark WM, Wissman S, Albers GW, Jhamandas JH, et al. (1999). Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. Journal of the American Medical Association, 282: 2019-2026.
  18. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from t-PA therapy? An analysis of patient eligibility. Neurology 2001; 56:1015-1020.
  19. Hacke W, Kaste M, Fieschi C, Toni D, et al. (1995). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. Journal of the American Medical Association, 274:1017-1025.

Downloads

Download data is not yet available.